Skip to main content

Table 3 Invitation to screening visit and outcome of first invitation letter, by trial a

From: Does offering an incentive payment improve recruitment to clinical trials and increase the proportion of socially deprived and elderly participants?

 

FAST (N = 332)

SCOT (N = 181)

PATHWAY 1 (N = 93)

PATHWAY 2 (N = 210)

PATHWAY 3 (N = 199)

Overall (N = 1,015)

Offered incentive payment, n (%)

158 (47.6%)

84 (46.4%)

46 (49.5%)

101 (48.1%)

92 (46.2%)

481 (47.4%)

Not offered incentive payment, n (%)

174 (52.4%)

97 (53.6%)

47 (50.5%)

109 (51.9%)

107 (53.8%)

534 (52.6%)

Number of responses to first invitation letter

Positive

      

 Incentive offer

68 (43.0%)

34 (40.5%)

5 (10.9%)

19 (18.8%)

26 (28.3%)

152 (31.6%)

 No incentive offer

54 (31.0%)

31 (32.0%)

7 (14.9%)

19 (17.4%)

21 (19.6%)

132 (24.7%)

% change with Incentive ((95% CI))

12.0%

8.5%

4.0%

1.4%

8.7%

6.9%* (1.35 to 12.40)

Negative

      

 Incentive offer

40 (25.3%)

15 (17.9%)

14 (30.4%)

30 (29.7%)

23 (25.0%)

122 (25.4%)

 No incentive offer

49 (28.2%)

16 (16.5%)

16 (34.0%)

37 (33.9%)

39 (36.4%)

157 (29.4%)

% change with incentive ((95% CI))

2.9%

1.4%

3.6%

4.2

11.4%

4.0% (−1.47 to 9.47)

No response

      

 Incentive offer

50 (31.6%)

35 (41.7%)

27 (58.7%)

52 (51.5%)

43 (46.7%)

207 (43.0%)

 No incentive offer

71 (40.8%)

50 (51.5%)

24 (51.1%)

53 (48.6%)

47 (43.9%)

245 (45.8%)

% change with incentive ((95% CI))

9.2%

9.8%

7.6%

2.9%

2.8%

2.8% (−3.27 to 8.92)

Number of patients signing a consent form

Incentive offer

58 (36.7%)

26 (30.9%)

3 (6.5%)

4 (4.0%)

9 (9.8%)

100 (20.8%)

No incentive offer

41 (23.6%)

24 (24.7%)

4 (8.5%)

9 (8.3%)

6 (5.6%)

84 (15.7%)

% change with incentive ((95% CI))

13.1%

6.2%

2.0%

4.3%

4.2%

5.1%* (0.31 to 9.85)

Number of patients randomised into trial

Incentive offer

58 (36.7%)

26 (30.9%)

2 (4.3%)

3 (3.0%)

5 (5.4%)

94 (19.5%)

No incentive offer

40 (23.0%)

24 (24.7%)

3 (6.4%)

6 (5.5%)

0

73 (13.7%)

% change with incentive ((95% CI))

13.7%

6.2%

2.1%

2.5%

5.4%*

5.9%* (1.30 to 10.49)

  1. aCI, Confidence interval; FAST, Febuxostat versus Allopurinol Streamlined Trial; PATHWAY, Prevention and Treatment of Hypertension with Algorithm Guided Therapy, British Heart Foundation–funded trials; SCOT, Standard care versus Celecoxib Outcome Trial. *P < 0.05.